COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Other Events

Item8.01 Other Events

On June12, 2017, Coherus BioSciences, Inc. (the Company) issued a
press release reporting the receipt of a complete response letter
from the U.S. Food and Drug Administration for its biologics
license application for CHS-1701, a pegfilgrastim (Neulasta)
biosimilar candidate on June9, 2017. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated by reference into this Item8.01.

On June9, 2017, the Patent Trial and Appeal Board (PTAB) of the
U.S. Patent and Trademark Office ruled in favor of the Companys
petitions for Inter Partes Review of AbbVies U.S. 9,017,680 and
9,073,987. The PTABs decision invalidates all claims of these
patents that were directed to a method for treating rheumatoid
arthritis by administering 40 mg of HUMIRA subcutaneously every
13 to 15 days.

Item9.01 Financial Statements and Exhibits.

About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS)

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial. Its long-acting granulocyte colony-stimulating factor (G-CSF) product candidate, CHS-1701, is a pegfilgrastim (Neulasta) biosimilar. Its clinical-stage pipeline consists of two anti-Tumor Necrosis Factors (anti-TNFs).